The European Society of Cardiology (ESC) released the "2024 ESC guidelines for the management of elevated blood pressure and hypertension" on August 30, 2024. This guideline updates the 2018 "Guidelines for the management of arterial hypertension." One notable update is the introduction of the concept of "elevated blood pressure" (120-139/70-89 mm Hg). Additionally, a new systolic blood pressure target range of 120-129 mm Hg has been proposed for most patients receiving antihypertensive treatment. The guideline also includes numerous additions or revisions in areas such as non-pharmacological interventions and device-based treatments for hypertension. This article interprets the guideline's recommendations on definition and classification of elevated blood pressure and hypertension, and cardiovascular disease risk assessment, diagnosing hypertension and investigating underlying causes, preventing and treating elevated blood pressure and hypertension. We provide a comparison interpretation with the 2018 "Guidelines for the management of arterial hypertension" and the "2017 ACC/AHA guideline on the prevention, detection, evaluation, and management of high blood pressure in adults."

Homo- or heterodimeric compounds that affect dimeric protein function through interaction between monomeric moieties and protein subunits can serve as valuable sources of potent and selective drug candidates. Here, we screened an in-house dimeric natural product collection, and panepocyclinol A (PecA) emerged as a selective and potent STAT3 inhibitor with profound anti-tumor efficacy. Through cross-linking C712/C718 residues in separate STAT3 monomers with two distinct Michael receptors, PecA inhibits STAT3 DNA binding affinity and transcription activity. Molecular dynamics simulation reveals the key conformation changes of STAT3 dimers upon the di-covalent binding with PecA that abolishes its DNA interactions. Furthermore, PecA exhibits high efficacy against anaplastic large T cell lymphoma in vitro and in vivo, especially those with constitutively activated STAT3 or STAT3^Y640F. In summary, our study describes a distinct and effective di-covalent modification for the dimeric compound PecA to disrupt STAT3 function.

Sanming launched substantial healthcare system reform in 2012,deeply recognizing that healthcare service price reform is an important healthcare system reform.Combined with the actual situation,Sanming systematically pushes forward the reform of medical service prices,dynamic adjustment and linkage reform,and explores the way that conforms to its own development,and has achieved better results.It primarily discusses the approaches,development outcomes,experiences,and insights of Sanming's healthcare service price reform.

Sanming launched substantial healthcare system reform in 2012,deeply recognizing that healthcare service price reform is an important healthcare system reform.Combined with the actual situation,Sanming systematically pushes forward the reform of medical service prices,dynamic adjustment and linkage reform,and explores the way that conforms to its own development,and has achieved better results.It primarily discusses the approaches,development outcomes,experiences,and insights of Sanming's healthcare service price reform.

Sanming launched substantial healthcare system reform in 2012,deeply recognizing that healthcare service price reform is an important healthcare system reform.Combined with the actual situation,Sanming systematically pushes forward the reform of medical service prices,dynamic adjustment and linkage reform,and explores the way that conforms to its own development,and has achieved better results.It primarily discusses the approaches,development outcomes,experiences,and insights of Sanming's healthcare service price reform.

Sanming launched substantial healthcare system reform in 2012,deeply recognizing that healthcare service price reform is an important healthcare system reform.Combined with the actual situation,Sanming systematically pushes forward the reform of medical service prices,dynamic adjustment and linkage reform,and explores the way that conforms to its own development,and has achieved better results.It primarily discusses the approaches,development outcomes,experiences,and insights of Sanming's healthcare service price reform.

Sanming launched substantial healthcare system reform in 2012,deeply recognizing that healthcare service price reform is an important healthcare system reform.Combined with the actual situation,Sanming systematically pushes forward the reform of medical service prices,dynamic adjustment and linkage reform,and explores the way that conforms to its own development,and has achieved better results.It primarily discusses the approaches,development outcomes,experiences,and insights of Sanming's healthcare service price reform.

Sanming launched substantial healthcare system reform in 2012,deeply recognizing that healthcare service price reform is an important healthcare system reform.Combined with the actual situation,Sanming systematically pushes forward the reform of medical service prices,dynamic adjustment and linkage reform,and explores the way that conforms to its own development,and has achieved better results.It primarily discusses the approaches,development outcomes,experiences,and insights of Sanming's healthcare service price reform.

Sanming launched substantial healthcare system reform in 2012,deeply recognizing that healthcare service price reform is an important healthcare system reform.Combined with the actual situation,Sanming systematically pushes forward the reform of medical service prices,dynamic adjustment and linkage reform,and explores the way that conforms to its own development,and has achieved better results.It primarily discusses the approaches,development outcomes,experiences,and insights of Sanming's healthcare service price reform.